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Abstract
Background: Intraductal papillary neoplasms of the biliary tract (IPNB) and intracholecystic papillary
neoplasms (ICPN) are rare tumours characterized by intraluminal papillary growth that can be associ-
ated with invasive carcinoma. Their natural history remains poorly understood. This study examines
clinicopathological features and outcomes.
Methods: Patients who underwent surgery for IPNB/ICPN (2008–2014) were identified. Descriptive
statistics and survival data were generated.
Results: Of 23 patients with IPNB/ICPN, 10 were male, and the mean age was 68 years. The most
common presentations were abdominal pain (n = 10) and jaundice (n = 9). Tumour locations were: int-
rahepatic (n = 5), hilar (n = 3), the extrahepatic bile duct (n = 8) and the gallbladder (n = 7). Invasive
cancer was found in 20/23 patients. Epithelial subtypes included pancreatobiliary (n = 15), intestinal
(n = 7) and gastric (n = 1). The median follow-up was 30 months. The 5-year overall (OS) and disease-
free survivals (DFS) were 51% and 57%, respectively. Decreased OS (P = 0.09) and DFS (P = 0.05)
were seen in patients with tumours expressing MUC1 on immunohistochemistry (IHC).
Conclusion: IPNB/ICPN are rare precursor lesions that can affect the entire biliary epithelium. At
pathology, the majority of patients have invasive carcinoma, thus warranting a radical resection.
Patients with tumours expressing MUC1 appear to have worse OS and DFSs.
Received 22 March 2015; accepted 25 May 2015
Correspondence
Guillaume Martel, The Ottawa Hospital – General Campus, 501 Smyth Road, Ottawa, ON, Canada,
K1H 8L6. Tel.: +1 613 737 8899 ext 71053. Fax: +1 613 739 6854. E-mail: gumartel@ottawahospital.on.ca
Introduction
Intrahepatic and extrahepatic cholangiocarcinoma (CC)
develop through a dysplasia-carcinoma sequence. Until
recently, the nomenclature and criteria for the classification of
biliary precursor lesions were not well established. At least two
major precursor lesions have been associated with the develop-
ment of invasive CC. The first is a microscopic lesion of flat or
micropapillary dysplastic epithelium, biliary dysplasia or biliary
intraepithelial neoplasia (BilIN).1,2 The second is an intraductal
papillary neoplasm of the bile duct, which is a macroscopic
lesion, single or multiple along the biliary tract, characterized
by intraluminal growth, prominent papillary proliferation of
dysplastic epithelium with frequent intestinal metaplasia and
mucin hypersecretion. These lesions were previously called
papillomas, papillary adenomas, papillomatosis (when multi-
ple) or mucin-secreting bile duct tumours. An intraductal pap-
illary neoplasm of the biliary tract (IPNB) was recognized as a
distinct pathological entity by the World Health Organization
in 2010.3–8 IPNB has widely been considered to be analogous
to an intraductal papillary mucinous neoplasm (IPMN) of the
pancreas.4,5,7,9–11 Both IPNB and IPMN feature intraluminal
growth, an association with mucin hypersecretion, and the
same four histological subtypes have been described: pancre-
atobiliary, intestinal, gastric and oncocytic.9,12 The same
tumour type occurring in the gallbladder is commonly referred
to as intracholecystic papillary neoplasm (ICPN).13
While there is an increasing body of literature on IPNB and
ICPN emerging from Asia, the North American experience
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remains limited. The largest North American series have iden-
tified 39 and 23 patients, respectively,11,14 and did not include
cases of ICPN. From the Asian literature, it is believed that
IPNB demonstrates a favourable prognosis compared with typ-
ical cholangiocarcinoma.7,15–17 This may be related to its intra-
luminal growth rather than a periductal infiltrating growth.
Compared with the Asian experience18,19, the North American
literature seems to demonstrate a higher proportion of invasive
carcinoma at the time of surgical resection.11,14 The objective
of this paper was to describe further the clinical and pathologi-
cal characteristics of a cohort of North American patients with
IPNB and ICPN.
Patients and methods
After approval from The Ottawa Health Science Research Eth-
ics Board (20140648-01H), a computerized search was per-
formed in the Anatomic Pathology archives. All cases between
March 2008 and September 2014 of resected gallbladder, intra-
hepatic, hilar and extrahepatic bile duct tumours, cross-refer-
enced with the words ‘cholangiocarcinoma’, ‘adenocarcinoma’,
‘intraductal’, ‘papilloma’, ‘papillomatosis’ or ‘papillary architec-
ture’, were retrieved from the surgical pathology files. Pancre-
atic intraductal papillary mucinous neoplasms, ampullary and
periampullary tumours of uncertain origin, and cases with in-
traductal epithelial dysplasia/neoplasia without compelling evi-
dence of intraductal mass formation were excluded.
All available tumour slides for the selected cases were
reviewed by an expert pathologist in the liver, biliary and pan-
creatic disease (ECM). Tumours were reclassified as IPNB/
ICPN with or without invasion according to the WHO classifi-
cation.8 The tumours were evaluated for architecture (papil-
lary, tubular or solid), epithelial type (intestinal, gastric,
oncocytic or pancreatobiliary), grade of dysplasia, the presence
and depth of invasion, lymphovascular invasion, perineural
invasion, lymph node metastasis and resection margin status.
The most representative tumour block from each case was
subjected to immunohistochemical (IHC) staining with MUC1
(clone Ma695, dilution 1:100; Leica Biosystems, Buffalo Grove,
IL, USA), MUC2 (clone B306-1, dilution 1:50; ABCAM, Cam-
bridge, MA, USA) and MUC5AC (clone CLH2, dilution 1:100;
Leica Biosystems, Buffalo Grove, IL, USA). Over 20 human
mucins (MUC1-MUC20) have been identified. Mucins can be
broadly subdivided into two groups: proteins that are secreted
and form extracellular gels (MUC2, MUC5AC, MUC5B and
MUC6) and membrane-bound mucins (MUC1, MUC3
and MUC4).20 In this cohort, the expression of MUC1,
MUC2, MUC5AC was evaluated semiquantitatively. Tumours
showing intense positive staining in more than 10% of tumour
cells were considered positive, as previously reported.20
Demographic, clinical, operative and imaging data were
retrieved retrospectively from patient records. Post-operative
complications were also retrieved from patient records and
classified using the Clavien–Dindo grading system. Survival
data were obtained from clinic notes and, in cases where fol-
low-up was conducted elsewhere, correspondence with the
treating oncologist. Overall survival was measured from the
date of surgical resection to the date of death. Patients still
alive at the date of last clinical encounter were censored. Dis-
ease-free survival was measured from the date of surgical resec-
tion to the date of first recurrence or death from the disease.
Patients were assumed to have died of disease unless they had
clear evidence to the contrary. Patients still alive at the date of
last clinical encounter and without evidence of disease recur-
rence were censored. Survival analysis was performed using the
Kaplan–Meier estimate of survival, and comparisons were
performed with the log-rank test. Statistical analysis was per-
formed with SAS 9.3 (SAS Institute Inc., Carry, NC, USA).
Results
Patients and pre-operative workup
Sixteen patients with IPNB and seven patients with ICPN were
identified. Demographics and clinical presentations are detailed
in Table 1. Most patients with IPNB presented in a manner typi-
cal of cholangiocarcinoma. Over two-thirds of patients had evi-
dence of biochemical biliary obstruction, whereas less than half
of patients had abdominal pain. All IPNB patients underwent
either computed tomography (CT) or magnetic resonance imag-
ing (MRI) pre-operatively. The majority of intrahepatic lesions
were found in the left hemiliver (four out of five). All patients
with IPNB went on to radical resection after cross-sectional
imaging and, occasionally, endoscopic cytology/histology results.
In contrast, patients with ICPN were more likely to present
incidentally or with symptoms suggestive of cholelithiasis
(6/7 patients). Specifically, two patients presented with epigastric
pain suggestive of biliary colic, one with pancreatitis, and one
with acalculous cholecystitis. One of the patients with biliary
colic had a mass on imaging prior to surgery whereas the other
three patients had no indication of having a gallbladder mass or
polyp. Two additional patients were asymptomatic and were
found to have a gallbladder mass or polyp incidentally. One
patient presented with an abdominal mass on examination. For
both IPNB and ICPN, serum carbohydrate antigen 19-9 (CA
19-9) was not routinely assessed during the pre-operative
work-up, but was used primarily for follow-up in select patients.
Surgical and pathological data
Surgical and pathological details are presented in Table 2.
Pre-operative tissue diagnosis was attempted as part of the pre-
operative workup in 10 patients with IPNB, whether by endo-
scopic retrograde cholangiopancreatography (ERCP) brushings,
ERCP biopsy of a visible duodenal tumour or by endoscopic
ultrasound (EUS) fine-needle aspiration. Despite the final
pathology results of microinvasive or invasive carcinoma in all
patients with IPNB, only 2/10 pre-operative histology/cytology
specimens were initially consistent with invasive malignancy.
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All three patients with ICPN who presented with pain and
did not have a mass on imaging went on to have a cholecystec-
tomy. All three had carcinoma in situ on final pathology. One
asymptomatic patient with a gallbladder polyp went on to lap-
aroscopic cholecystectomy and was found to have a T3 carci-
noma with negative margins. He declined further liver surgery.
All three other ICPN patients who had either a palpable mass
or mass on pre-operative imaging were considered to have
gallbladder cancer and went on to have a cholecystectomy and
liver resection. Among cases of ICPN, invasive cancer was seen
in three of the five tumours with a pancreatobiliary subtype,
and the one with a gastric subtype. The ICPN tumour with an
intestinal subtype was non-invasive.
An R0 resection was achieved for all patients with ICPN and
12/16 patients with IPBN. Among the four patients with R1
resections, two patients had false-negative intra-operative fro-
zen section bile duct margin analyses, one was unfit for more
extensive radical resection, and one had intraductal tumour
infiltration within the remnant liver.
After pathological review for this work, 9/23 tumours were
re-classified as IPNB/ICPN with or without invasion. Original
reports included terms such as ‘papillary adenoma‘, ‘villous
adenoma‘, ‘billiary papillomatosis‘ or ‘papillary differentiation‘.
All included tumours showed a visible intraluminal growth
(Fig. 1a) with papillary fronds showing delicate fibrovascular
cores, lined by dysplastic epithelium (Fig. 1b, c). The most
common histological subtype was pancreatobiliary (Fig. 1d),
followed by an intestinal type (Fig. 1e) and a single tumour
with a gastric phenotype (Fig. 1f). No tumour showed onco-
cytic features.
MUC1 was expressed in the luminal border and cytoplasm
of cancer cells. MUC2 and MUC5AC were mainly expressed in
the cytoplasm of tumour cells. MUC1 was expressed predomi-
nantly in the pancreatobiliary subtype, whereas the intestinal
type showed constant expression of MUC2 (Table 3).
Outcomes
Seven patients experienced a post-operative complication
(Clavien–Dindo grade 2 or higher), of which 3 patients had
grade 3a complications. These included three cases of percuta-
neous drain insertion for a pancreatic fistula (n = 1) and bile
leaks after a hepaticojejunostomy (n = 2). Grade 2 complica-
tions included three cases of antibiotics therapy for small
undrained collections and one case of a blood transfusion.
There were no complications requiring intensive care, and no
mortalities.
Nine of the sixteen patients with IPNB underwent adjuvant
chemotherapy, most commonly gemcitabine and cisplatin. One
out of seven ICPN patients underwent adjuvant chemotherapy.
The median follow-up of patients was 30 months. There
were seven patients who developed a recurrence of cancer: four
with intrahepatic metastases, one with distant metastases, and
two with both local recurrence and distant metastases. Five of
the recurrences occurred in patients with distal extrahepatic
primary cancers, and two in patients with gallbladder lesions.
The furthest recurrence from the time of surgery was
22 months. Among patients with recurrence, six died, and one
additional patient died without evidence of disease recurrence.
The OS at 3 and 5 years was 71% and 51%, respectively.
Disease-free survival was 57% at both 3 and 5 years. There was
no significant difference in OS and DFS for an R1 resection
(P = 0.20 and 0.37) and epithelial subtype (P = 0.62 and 0.34).
Similarly, there was no difference in OS or DFS when compar-
ing micro-invasive and invasive tumours (P = 0.91 and 0.73).
Patients with tumours expressing MUC1 demonstrated a
decreased OS (P = 0.09), and DFS (P = 0.05). No other immu-
nohistochemical markers were associated with prognosis. Fig-
ure 2 displays the Kaplan–Meier survival curves for OS and
DFS for all 23 patients, and for the comparison of patients
with and without expression of MUC1.
Discussion
The present study describes the clinical and pathological char-
acteristics of patients undergoing surgery for IPNB and ICPN.
It adds to a relatively limited body of literature on this topic,
particularly in North America.
The current paper demonstrates that patients with IPNB or
ICPN tend to present similarly to patients with typical cholan-
giocarcinoma or gallbladder cancer, albeit with occasional
Table 1 Patient characteristics (n = 23)
Variable IPNB (n = 16) ICPN (n = 7)
Age at diagnosis (mean  SD) 70.1  9.6 64.1  12.9
Male 9 1
Presentation
Jaundice 9 0
Abdominal Pain 6 4
Palpable mass 0 1
Incidental finding on imaging 1 2
Elevated AST/ALT 10 1
Elevated ALP 11 0
Pre-operative imaging
Ultrasound 5 7
CT scan 13 4
MRI 12 2
ERCP 11 0
EUS 3 0
AST, aspartate aminotransferase; ALT, alanine transaminase; ALP,
alkaline phosphatase; CT, computed tomography; ERCP, endoscopic
retrograde cholangiopancreatography; EUS, endoscopic ultrasound;
ICNB, intracholecystic papillary neoplasm; IPNB, intraductal papillary
neoplasm of the biliary tract; MRI, magnetic resonance imaging; n,
number of patients; SD, standard deviation.
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abdominal pain. Usually, the diagnosis of IPNB/ICPN was not
established until the final surgical specimen is reviewed. The
use of pre-operative endoscopic histology/cytology was not
particularly reliable in establishing a diagnosis of malignancy
(2/10), possibly owing to limited foci of invasive disease. At
final pathology, the rate of invasive cancer amongst patients
with intrahepatic, hilar, or distal extrahepatic IPNB was 100%,
whereas that with ICPN of the gallbladder was 57%. This high
rate of invasive disease among patients with IPNB is consistent
with other North American papers but is higher than most
Asian series.18,19 The discrepancy in the rates of invasion
between the two continents is not entirely understood. Hepato-
lithiasis and liver fluke infection have been identified as risk
factors among Asian patients,4,9,10,18,21,22 which may hint at a
difference in pathophysiology. It may also explain the overall
increased burden of disease in Asia. Earlier diagnosis or genetic
differences may also play a role. At least one other series has
noted that ICPN was more common in Asia, whereas a gall-
bladder lesion from flat dysplasia was more frequent in the
West.23 Consistent with other series,4,7,14,19,24 the current study
found the majority (80%) of intrahepatic IPNBs to be within
the left hemiliver.
As described earlier, IPNB/ICPN is a precursor lesion to
invasive cholangiocarcinoma and gallbladder carcinoma that is
now considered distinct from the more common BilIN.8 IPNB/
ICPN leads to macroscopically visible intraluminal lesions,
whereas BilIN is typically ‘flat‘ and macroscopically non-
tumour forming.8,25 When associated with BilIN, invasive car-
cinoma usually demonstrates a desmoplastic stromal reaction
and tubular pattern.25 In contrast, IPNB/ICPN, which accounts
for 10–15% of biliary tumours, lead to biliary or cholecystic
luminal papillary tumour growth.25 As a result of tumour fill-
ing (with or without mucin), the latter leads to cystic or fusi-
form dilation of the bile duct.25 These lesions appear to be
more common in the extrahepatic biliary tree (2:1), although
they can be found synchronously in both the intra- and extra-
hepatic bile ducts.25 IPNB/ICPN would also appear to be much
more commonly associated with early symptoms of intermit-
tent pain, jaundice or cholangitis.
Table 2 Surgical and pathological characteristics
Variable IPNB (n = 16) ICPN (n = 7)
Anatomic location
Left intrahepatic
bile ducts
4 N/A
Right intrahepatic
bile ducts
1 N/A
Liver hilum 3 N/A
Common bile duct 8 N/A
Pre-operative histology/cytology (n = 10)
Negative 2 N/A
Cytologic atypia 1 N/A
Suspicious for
malignancy
1 N/A
High grade dysplasia 4 N/A
Adenocarcinoma 2 N/A
Surgery performed
Left hepatectomy 4
Segmental resection 2
Pancreaticoduo-
denectomy
5
Choledochectomy 5
Lap cholecystectomy 3
Open cholecystectomy 1
Open cholecystectomy +
liver wedge
3
R0 resection 12 7
R1 resection 4 0
Epithelial subtype
Pancreatobiliary 10 5
Intestinal 6 1
Gastric 0 1
Mean tumour size
(cm  SD)
3.1  2.0 6.2  7.3
Non-invasive 0 3
Microinvasion (<5 mm) 4 2
Invasion (>5 mm) 12 2
T stage
Tis 0 3
1 7 1
2a 7 1
3 2 2
N stage
X 4 3
0 8 4
1 2 0
2 2 0
Table 2 Continued
Variable IPNB (n = 16) ICPN (n = 7)
Lymphovascular
Invasion present
6 (n = 15)b 3 (n = 6)
Perineural Invasion
Present
6 (n = 13) 0 (n = 5)
a
Combines T2, T2a, T2b (each anatomic location has unique T stag-
ing).
b
not all pathology reports commented on lymphovascular or perineural
invasion.
cm, centimetre; mm, millimetre; n, number of patients; SD, standard
deviation.
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Both IPNB and ICPN were included in the present study, as
the pathophysiological process of papillary tumour growth
within the biliary lumen appears to be the same for both
tumour types.8,13 Clinically and anatomically, however, IPNB
and ICPN behave differently in terms of presentation and sur-
gical management. For this reason, both tumours were divided
when describing presentation, management and outcomes. Fur-
thermore, this is particularly relevant as the description of
ICPN in the literature is in its infancy.13,23,26 The definition,
described by Adsay et al.13, is of an exophytic intramucosal
gallbladder mass greater than 1 cm and composed of dysplastic
cells forming a lesion distinct from the neighbouring mucosa.
The current paper represents one of the first surgical series to
describe gallbladder lesions using this system.
In terms of epithelial subtypes, IPNB tumours demonstrated
only pancreatobiliary and intestinal, with a slightly higher prev-
alence of pancreatobiliary. This is similar to other published
reports,11,14 although gastric and oncocytic subtypes were also
seen in small numbers. ICPN tumours, which were not
included in the other North American series, also demonstrate
mostly a pancreatobiliary subtype. This series found no cases
of an oncocytic epithelial subtype.
The 5-year OS and DFS for this series were 51% and 57%,
respectively, and did not differ significantly between the patients
(a)
(b)
(d)
(c)
(e) (f)
Figure 1 (a) Liver left hepatectomy surgical resection specimen, showing a large papillary tumour filling the dilated intrahepatic bile ducts
(thick arrows). (b) Tumour depicted in (a), showing the intraductal papillary neoplasm (IPNB) that fills the bile duct lumen and spreads
along the biliary tree (thick arrows). An area of invasive adenocarcinoma into the liver parenchyma is noted, tubular type, poorly
differentiated (thin arrow). Hematoxylin and eosin (H&E) stain, 29 magnification. (c) IPNB, common bile duct (thick arrows). Invasive
adenocarcinoma is present, tubular type, invading the duct wall into the periductal adipose tissue (thin arrow). H&E stain,
29 magnification. (d) IPNB, pancreatico-billiary type. Tumour cells resemble biliary or pancreatic epithelium, are composed of columnar
cells or low cuboidal cells with eosinophilic cytoplasm and round nuclei. H&E stain (200x). (e) IPNB, intestinal type. Tumour cells
resemble intestinal adenoma or adenocarcinoma and are characterized by stratified tall columnar cells with some goblet cells. H&E stain
(200x). (f) IPNB, gastric type. Tumour cells resemble gastric epithelium and are composed of columnar cells with abundant
intracytoplasmic mucin. H&E stain (200x)
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with IPNB and ICPN. This is similar to the 62 month OS previ-
ously reported,14 and slightly higher than the 38% 5-year OS
reported by Barton et al.11 All of these data indicate that IPNB
may confer an improved prognosis when compared with typical
cholangiocarcinoma, as suggested in the Asian literature. That
being said, it remains unclear whether this observation is related
to an earlier presentation for most patients or whether, these
tumours truly have a better biological prognosis, stage for stage.
Furthermore, the present study adds to previously published evi-
dence that MUC1 immunohistochemical staining is a poor prog-
nostic marker in IPNB.14 MUC1 was the only factor that showed
a statistically significant difference when comparing survival
curves. An increased depth of invasion and R1 resection, both
well-established negative prognostic factors in surgical oncology,
did not reach statistical significance for OS and DFS.
Interestingly, all five patients with IPNB who experienced
disease recurrence were among those with distal extrahepatic
bile duct primary tumours. As no patients in the intrahepatic
or hilar groups had a recurrence, comparison of survival curves
or univariate analysis is not appropriate as there were no
events. An increased risk of recurrence has not been associated
with the anatomical location in other papers, and it is difficult
to draw any conclusions from such a small sample.
It has been suggested from the Asian literature that pre-
operative cholangioscopy and an intra-operative frozen section
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Figure 2 Kaplan–Meier survival curves for (a) overall survival, (b) disease-free survival, (c) overall survival with/without MUC1, and (d)
disease-free survival with/without MUC1
Table 3 Immunohistochemical characteristics of IPNB/ICPN
(n = 22)
Epithelial subtype MUC1 MUC2 MUC5AC
Pancreatobiliarya 11/14 2/14 8/14
Intestinal 2/7 7/7 4/7
Gastric 0/1 0/1 1/1
Total 13/22 9/22 13/22
a
One specimen was not available for immunohistochemical profiling.
n, number of patients.
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be more routinely used in patients with IPNB.4,10 The hypoth-
esis being that with IPNB’s intraluminal growth, these modali-
ties may better delineate the extent of disease, and increase the
likelihood of an R0 resection. Given that the majority of
patients in the North American setting do not have an estab-
lished pre-operative diagnosis of IPNB, this may not prove fea-
sible. Further research on the utility of these tools in the
setting of IPNB is required. A pre-operative cholangioscopy
was not performed on any of the patients in this series, and an
intra-operative frozen section was used at the surgeon’s discre-
tion. At least two patients had false-negative frozen sections,
leading to R1 resection.
The major strength of this paper is the contribution of clini-
cal and pathological data about patients with a disease that is
poorly described in North America. To date, only two other
papers have described a series of patients this large. The med-
ian follow-up of 30 months is robust, and the patient popula-
tion is recent. Furthermore, it is only the second North
American paper to report the immunohistochemical features
of these tumours.14 Limitations of this paper include its small
sample size, making it difficult to demonstrate statistically sig-
nificant results in comparative survival analyses. The retrospec-
tive nature of the study also introduces limitations and biases
into the data collection process. For the specimens with inva-
sive cancer, all were found to be tubular adenocarcinoma. It
has been shown that mucinous carcinoma demonstrates
improved survival compared with tubular,6 but this relation-
ship cannot be studied in this series. Compared with other
studies, fewer IHC markers were utilized. The IHC markers
chosen were those typically performed at our institution. Also,
the majority of patients in this series did not undergo a pre-
operative serum CA 19-9 test, and, therefore, its utility as a
prognostic tool cannot be studied.
Conclusion
IPNB and ICPN are rare precursor lesions that can affect the
entire biliary epithelium. At pathology, the majority of patients
have invasive carcinoma, thus warranting a radical resection.
Prognosis may be superior to traditional cholangiocarcinoma
and gallbladder cancer. Patients with tumours expressing
MUC1 appear to have worse OS and DFSs.
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